Compare WS & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WS | ZYME |
|---|---|---|
| Founded | 1955 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.0B |
| IPO Year | N/A | 2017 |
| Metric | WS | ZYME |
|---|---|---|
| Price | $36.00 | $26.98 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $37.50 | $30.67 |
| AVG Volume (30 Days) | 271.3K | ★ 963.2K |
| Earning Date | 12-17-2025 | 11-06-2025 |
| Dividend Yield | ★ 1.76% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.47 | N/A |
| Revenue | ★ $3,265,100,000.00 | $134,481,000.00 |
| Revenue This Year | $12.50 | $64.45 |
| Revenue Next Year | $3.97 | $67.04 |
| P/E Ratio | $14.71 | ★ N/A |
| Revenue Growth | N/A | ★ 116.21 |
| 52 Week Low | $21.30 | $9.03 |
| 52 Week High | $38.59 | $28.49 |
| Indicator | WS | ZYME |
|---|---|---|
| Relative Strength Index (RSI) | 62.92 | 65.59 |
| Support Level | $34.34 | $24.88 |
| Resistance Level | $38.59 | $26.55 |
| Average True Range (ATR) | 1.42 | 1.13 |
| MACD | -0.05 | -0.21 |
| Stochastic Oscillator | 43.84 | 84.07 |
Worthington Steel Inc is a processor of carbon flat-rolled steel, a producer of laser-welded solutions, and a provider of electrical steel laminations. The company has manufacturing facilities across the United States, Canada, China, India, Germany and Mexico. It buys coils of steel from primary steel producers and processes them to precise type, thickness, length, width, shape, and surface quality required by customer specifications. The company's product lines and processing capabilities include; carbon flat-rolled steel processing, electrical steel laminations, and tailor welded products. Geographically, the company generates a majority of its revenue from the United States followed by Canada, Mexico, and other regions.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.